Barrett's esophagus is characterized by the absence of Helicobacter pylori infection and high levels of serum pepsinogen I concentration in Japan

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 1, 2009, Pages 129-134

  Abe, Yasuhiko ^a,b   Iijima, Katsunori ^a   Koike, Tomoyuki ^a   Asanuma, Kiyotaka ^a   Imatani, Akira ^a   Ohara, Shuichi ^a   Shimosegawa, Tooru ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NONE   (Japan)

Author keywords

Barrett's esophagus; H. pylori infection; Serum pepsinogen

Indexed keywords

GASTRIN; IMMUNOGLOBULIN G ANTIBODY; PEPSINOGEN I; PEPSINOGEN II;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BARRETT ESOPHAGUS; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 58549095656     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05691.x     Document Type: Article

References (46)

1. Spechler SJ. Barrett's esophagus. N. Engl. J. Med. 1986 315 : 362 71.
2. Eisen GM, Sandler RS, Murray S, Gottfried M. The relationship between gastroesophageal reflux disease and its complication with Barrett's esophagus. Am. J. Gastroenterol. 1997 92 : 27 31.
3. Cameron AJ, Lomboy CT, Pera M, Carpenter HA. Adenocarcinoma of esophagogastric junction and Barrett's esophagus. Gastroenterology 1995 109 : 1541 6.
4. Hirota WK, Loughney TM, Lazas DJ, Maydonovitch CL, Rholl V, Wong RK. Specialized intestinal metaplasia, dysplasia and cancer of esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology 1999 116 : 277 85.
5. Devesa S, Blot W, Fraumeni J. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998 83 : 2049 53.
6. Dickman R, Bautista JM, Wong WM et al. Comparison of esophageal acid exposure distribution along the esophagus among the different gastroesophageal reflux disease (GERD) groups. Am. J. Gastroenterol. 2006 101 : 2463 9.
7. Zentilin P, Conio M, Mele MR et al. Comparison of the main oesophageal pathophysiological characteristics between short- and long-segment Barrett's oesophagus. Aliment. Pharmacol. Ther. 2002 16 : 893 8.
8. Mulholland MW, Reid BJ, Levine DS, Rubin CE. Elevated gastric acid secretion in patients with Barrett's metaplastic epithelium. Dig. Dis. Sci. 1989 34 : 1329 34.
9. Collen MJ, Johnson DA, Sheridan MJ. Basal acid output and gastric acid hypersecretion in gastroesophageal reflux disease. Correlation with ranitidine therapy. Dig. Dis. Sci. 1994 39 : 410 17.
10. Gerson LB, Boparai V, Ullah N, Triadafilopoulos G. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors. Aliment. Pharmacol. Ther. 2004 20 : 637 43.
11. Malfertheiner P, Lind T, Willich S et al. Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study. Gut 2005 54 : 746 51.
12. Johansson KE, Ask P, Boeryd B, Fransson SG, Tibbling L. Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease. Scand. J. Gastroenterol. 1986 21 : 837 47.
13. Hirschowitz BI. Gastric acid and pepsin secretion in patients with Barrett's esophagus and appropriate controls. Dig. Dis. Sci. 1996 41 : 1384 91.
14. Sipponen P, Kekki M, Seppälä K, Siurala M. The relationship between chronic gastritis and gastric acid secretion. Aliment. Pharmacol. Ther. 1996 10 (Suppl. 1 103 18.
15. Koike T, Ohara S, Sekine H et al. Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut 2001 49 : 330 4.
16. Abe Y, Ohara S, Koike T et al. The prevalence of Helicobacter pylori infection and the status of gastric acid secretion in patients with Barrett's esophagus in Japan. Am. J. Gastroenterol. 2004 99 : 1213 21.
17. Samloff IM. Cellular localization of group I pepsinigen in human gastric mucosa by immunofluorescence. Gastrotenterology 1971 61 : 185 8.
18. Samloff IM, Liebman WM. Cellular localization of group II pepsinigens in human stomach and duodenum by immunofluorescence. Gastrotenterology 1973 65 : 36 42.
19. Borch K, Axelsson CK, Halgreen H et al. The ratio of pepsinogen A to pepsinogen C: a sensitive test for atrophic gastritis. Scand. J. Gastroenterol. 1989 24 : 870 6.
20. Feldman M, Richardson CT, Lam SK, Samloff IM. Comparison of gastric acid secretion rates and serum pepsinogen I and II concentrations in Occidental and Oriental duodenal ulcer. Gastroenterology 1988 95 : 630 5.
21. Kiyohira K, Yoshihara M, Ito M, Haruma K, Tanaka S, Chayama K. Serum pepsinogen concentration as a marker of Helicobacter pylori infection and the histologic grade of gastritis; evaluation of gastric mucosa by serum pepsinogen levels. J. Gastroenterol. 2003 38 : 332 8.
22. Derakhshan MH, El-Omar E, Oien K et al. Gastric histology, serological markers and age as predictors of gastric acid secretion in patients infected with Helicobacter pylori. J. Clin. Pathol. 2006 59 : 1293 9.
23. Iijima K, Sekine H, Koike T, Imatani A, Ohara S, Shimosegawa T. Serum pepsinogen concentrations as a measure of gastric acid secretion in Helicobacter pylori-negative and -positive Japanese subjects. J. Gastroenterol. 2005 40 : 938 44.
24. Dockray GJ. Topical review. Gastrin and gastric epithelial physiology. J. Physiol. 1999 518 : 315 24.
25. McGowan CC, Cover TL, Blaser MJ. Helicobacter pylori and gastric acid: biological and therapeutic implications. Gastroenterology 1996 110 : 926 38.
26. Sampliner RE, The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am. J. Gastroenterol. 2002 97 : 1888 95.
27. Armstrong D, Bennett JR, Blum AL et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996 111 : 85 92.
28. Evans DJ, Evans DG, Graham DY et al. A sensitive and specific serologic test for detection of Campylobacter pylori infection. Gastroenterology 1989 96 : 1004 8.
29. Ichinose M, Miki K, Furihata C et al. Radioimmunoassay of serum group I and group II pepsinogens in normal controls and patients with various disorders. Clin. Chim. Acta 1982 126 : 183 91.
30. Yalow RS, Berson SA. Radioimmunoassay of gastrin. Gastroenterology 1970 58 : 1 14.
31. Asaka M, Kimura T, Kudo M et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology 1992 102 : 760 6.
32. Iftikhar SY, James PD, Steele RJ, Hardcastle JD, Atkinson M. Length of Barrett's oesophagus: an important factor in the development of dysyplasia and adenocarcinoma. Gut 1992 33 : 1155 8.
33. Anandasabapathy S, Jhamb J, Davila M, Wei C, Morris J, Bresalier R. Clinical and endoscopic factors predict higher pathologic grade of Barrett dysplasia. Cancer 2007 109 : 668 74.
34. Odze RD. Unraveling the mystery of gastroesophageal junction: a pathologist's perspective. Am. J. Gastroenterol. 2005 100 : 1853 67.
35. Sharma P, Morales TG, Sampliner RE. Short segment Barrett's esophagus - the need for standardization of the definition and of endoscopic criteria. Am. J. Gastroenterol. 1998 93 : 1033 6.
36. Hongo M. Review article: Barrett's esophagus and carcinoma in Japan. Aliment. Pharmacol. Ther. 2004 20 (Suppl. 8 50 4.
37. Kim JY, Kim YS, Jung MK et al. Prevalence of Barrett's esophagus in Korea. J. Gastroenterol. Hepatol. 2005 20 : 633 6.
38. Zhang J, Chen XL, Wang KM, Guo XD, Zuo AL, Gong J. Relationship of gastric Helicobacter pylori infection to Barrett's esophagus and gastro-esophageal reflux disease in Chinese. World J. Gastroenterol. 2004 10 : 672 5.
39. Rajendra S, Ackroyd R, Robertson IK, Ho JJ, Karim N, Kutty KM. Helicobacter pylori, ethnicity, and the gastroesophageal reflux disease spectrum: a study from the East. Helicobacter 2007 12 : 177 83.
40. Sipponen P, Vauhkonen M, Helske T, Kaariainen I, Harkonen M. Low circulating levels of gastrin-17 in patients with Barrett's esophagus. World J. Gastroenterol. 2005 11 : 5988 92.
41. Mulholland G, Ardill JE, Fillmore D, Chittajallu RS, Fullarton GM, McColl KE. Helicobacter pylori related hypergastrinaemia is the result of a selective increase in gastrin 17. Gut 1993 34 : 757 61.
42. Miki K, Morita M, Sasajima M, Hoshina R, Kanda E, Urita Y. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am. J. Gastroenterol. 2003 98 : 735 9.
43. Kitahara F, Kobayashi K, Sato T, Kojima Y, Araki T, Fujino MA. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut 1999 44 : 693 7.
44. Oishi Y, Kiyohira Y, Kubo M et al. The serum pepsinogen test as a predictor of gastric cancer. The Hisayama study. Am. J. Epidemiol. 2006 163 : 629 37.
45. Urita Y, Hike K, Torii N et al. Comparison of serum IgA and IgG antibodies for detecting Helicobacter pylori infection. Intern. Med. 2004 43 : 548 52.
46. Maeda S, Yoshida H, Ogura K et al. Assessment of gastric carcinoma risk associated with Helicobacter pylori may vary depending on the Antigen used: CagA specific enzyme-linked immunoadsorbent assay (ELISA) versus commercially available H. pylori ELISAs. Cancer 2000 88 : 1530 5.